You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

84 search results for: asthma

Type 2 Inflammation Underpins Pediatric Severe <b>Asthma</b>

Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

Importance of Lung Function Assessment in Pediatric <b>Asthma</b> Patients

videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

3 min

Pulmonology

Review the burden associated with lung function decline in pediatric patients with severe asthma, and the value of clinical lung function assessments.

ERS 2023 | Adult <b>Asthma</b> Symposium: Mini Debate

expert video

ERS 2023 | Adult Asthma Symposium: Mini Debate

3 min

Pulmonology

Prof. Ian Pavord moderates a debate between Prof. Vibeke Backer and Dr. Francesca Puggioni about what a patient's lung function should be in order to be defined as achieving clinical remission in adult asthma.

Type 2 Inflammation Mediates Severe <b>Asthma</b> in Pediatric Patients

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Clinical Remission as a Goal in <b>Asthma</b> Clinical Practice

expert video

Clinical Remission as a Goal in Asthma Clinical Practice

2 min

Pulmonology

Profs. Alberto Papi and Ian Pavord discuss clinical remission as a goal in asthma clinical practice beyond symptom control

Airway Remodeling in Type 2 <b>Asthma</b> is Driven by IL-4 and IL-13

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

FeNO: A Biomarker of Type 2 Inflammation in Pediatric <b>Asthma</b> Patients

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma

Why Is It Important to Assess Lung Function in Pediatric <b>Asthma</b>

interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

5 min

Pulmonology

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma

Adult <b>Asthma</b> Interactive Patient Cases

interactivity

Adult Asthma Interactive Patient Cases

15 min

Pulmonology

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma

Pediatric <b>Asthma</b> Patient Case Tool: Ash

interactivity

Pediatric Asthma Patient Case Tool: Ash

5 min

Pulmonology

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

The Cycle of Inflammation in Adult <b>Asthma</b>

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients

Burdens Experienced by Pediatric <b>Asthma</b> Patients and Their Caregivers

expert video

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers

3 min

Pulmonology

Drs. Michael Blaiss and Bob Geng discuss the burdens experienced by pediatric severe asthma patients and their caregivers.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region